Developing drug prototypes: Pharmacology replaces safety and tolerability?

Nature Reviews Drug Discovery

Volumn 9, Issue 11, 2010, Pages 856-865

  Cohen, Adam F ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; KNOWLEDGE MANAGEMENT; METHODOLOGY; MORBIDITY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STATISTICAL MODEL; TOXICITY TESTING; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; MAXIMUM TOLERATED DOSE; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY, CLINICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78049465934     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3227     Document Type: Review

References (46)

1. William Withering. An Account of the Foxglove and its Medical Uses (Oxford Univ. Press, London, 1785).
2. Ng, R. Drugs. From discovery to approval 2nd edn (John Wiley & Sons, Hoboken, New Jersey, 2009).
3. Rang, H. P. Drug Discovery and Development. 1st edn (Churchill Livingstone, Elsevier, Philadelphia, 2007).
4. Cross, J. et al. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol. Drug Saf. 11 , 439-446 (2002).
5. Bhogal, N. & Combes, R. TGN1412: time to change the paradigm for the testing of new pharmaceuticals. Altern. Lab. Anim. 34, 225-239 (2006).
6. Clark, R. W. et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24, 490-497 (2004).
7. Zhao, L., Jin, W., Rader, D., Packard, C. & Feuerstein, G. A translational medicine perspective of the development of torcetrapib: does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and translational medicine in atherosclerosis drug discovery and development. Biochem. Pharmacol. 78, 315-325 (2009).
8. US Food and Drug Administration. Note for guidance on general considerations for clinical trials. Fed. Regist. 62(242), 66113-66119 (1997).
9. Lenfle, S. & Loch, C. Lost roots. How project management settled on the phased approach (and compromised its ability to lead change in modern enterprises). Ecole Polytechnique website [online], http://crg.polytechnique.fr/ fichiers/crg/publications/ pdf/2010-03-06-1630.pdf (2009).
10. Loch, C., DeMeyer, A. & Pich, M. Managing the unknown. A new approach to managing high uncertainty and risk in projects. (John Wiley & Sons, Hoboken, New Jersey, 2006).
11. Shuchman, M. Commercializing clinical trials-risks and benefits of the CRO boom. N. Engl. J. Med. 357, 1365-1368 (2007).
12. Bresalier, R. S. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092-1102 (2005).
13. Garnier, J. P. Rebuilding the R&D engine in big pharma. Harv. Bus Rev. 86, 68-70, 72-76, 128 (2008).
14. Cuatrecasas, P. Drug discovery in jeopardy. J. Clin. Invest. 11 6 , 2837-2842 (2006).
15. Munos, B. Lessons from 60 years of pharmaceutical innovation. Nature R e v. Drug Discov. 8, 959-968 (2009).
16. Lehman Brothers. The fruits of genomics. Drug pipelines face indigestion until the new biology ripens. (Lehman Brothers, New York, 2001).
17. US Food and Drug Administration. Challenge and opportunity on the critical path to new medical products. FDA website [online], http://www.fda.gov/ downloads/Drugs/ScienceResearch/ResearchAreas/ ucm079290.pdf (2004).
18. Loch, C., Mihm, J. & Huchzermeier, A. Concurrent engineering and design oscillations in complex engineering projects. Concurrent Eng. 11 , 187-199 (2003).
19. Allen, T., Thusman, M. & Lee, D. Technology transfer as a function of position in the spectrum from research through development to technical services. Acad. Manage. J. 22, 694-708 (1979).
20. Roussel P. A., Saad, K. N. & Erickson, T. J. Third generation R&D: Managing the Link to Corporate Strategy 1st edn (Harvard Bus School Press, Boston, Massachusetts, USA, 1991).
21. Sheiner, L. B. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61, 275-291 (1997).
22. Danhof, M., Alvan, G., Dahl, S. G., Kuhlmann, J. & Paintaud, G. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm. Res. 22, 1432-1437 (2005).
23. FDA Center for Drug Evaluation and Research. Exploratory I.N.D. Studies. FDA website [online], http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ucm078933.pdf (2006).
24. Kenter, M. J. & Cohen, A. F. Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet 368, 1387-1391 (2006).
25. Cohen, A. Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies. Clin. Pharmacokinet. 47, 373-381 (2008).
26. FDA Center for Drug Evaluation and Research. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Guidance for Industry. FDA website [online], http://www.fda.gov/do= wnloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ucm078932.pdf (2005).
27. Cohen, A. Should we tolerate tolerability as an objective in early drug development? Br. J. Clin. Pharmacol. 64, 249-252 (2007).
28. Schein, P. S. et al. The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man. Clin. Pharmacol. Ther. 11 , 3-40 (1970).
29. Freireich, E. J., Gehan, E. A., Rall, D. P. , Schmidt, L. H. & Skipper, H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother. Rep. 50, 219-244 (1966).
30. Zhou, H. et al. Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). J. Clin. Pharmacol. 39, 911-919 (1999).
31. Appel, S., Kumle, A., Hubert, M. & Duvauchelle, T. First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist. J. Clin. Pharmacol. 37, 229-237 (1997).
32. Chan K. Y. et al. Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries. Eur. J. Pharmacol. 619, 61-67 (2009).
33. Farzaneh, L., Kasahara, N. & Farzaneh, F. The strange case of TGN1412. Cancer Immunol. Immunother. 56, 129-134 (2007).
34. (-/-) mice. Blood 108, 238-245 (2006).
35. Expert Scientific Group on Phase One clinical Trials. Final Report (The Stationary Office, Norwich, UK, 2006 ).
36. De Visser, S. J. et al. Concentration-effect relationships of two rilmenidine single-dose infusion rates in hypertensive patients. Clin. Pharmacol. Ther. 72, 419-428 (2002).
37. Van Der Post, J. P., de Visser, S. J., Schoemaker, R. C., Cohen, A. F. & van Gerven, J. M. Pharmacokinetic/ pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients. J. Psychopharmacol. 18, 221-227 (2004).
38. De Visser, S. J. et al. Biomarkers for the effects of benzodiazepines in healthy volunteers. Br. J. Clin. Pharmacol. 55, 39-50 (2003).
39. Brisbare-Roch, C. et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nature Med. 13, 150-155 (2007).
40. De Visser, S. J. A question based approach to drug development. Thesis, Leiden Univ. (2003).
41. Aronson, J. K. & Ferner, R. E. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 327, 1222-1225 (2003).
42. Franson, K. L. & Cohen, A. F. How it works. Br. J. Clin. Pharmacol. 68, 315-317 (2009).
43. Brunton, L., Blumenthal, D., Buxton, I. & Parker, K. Goodman and Gilman's Manual of Pharmacology and Therapeutics (McGraw Hill Medical, USA, 2006).
44. Dollery, C. T. Clinical pharmacology in the molecular era. Clin. Pharmacol. Ther. 83, 220-225 (2008).
45. Aronson, J. An account of the foxglove and its medical uses, 1785-1985. (Oxford Univ. Pres, London 1985). Clin. Pharmacol. Ther. 83, 220-225 (2008).
46. Van Gerven, J. M. et al. Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br. J. Clin. Pharmacol. 44, 487-493 (1997).